sr 1

SSR 180 is a potent and subtype-selective α7 agonist with applications in the study of Alzheimer;s disease and schizophrenia.

SR 11302 is an inhibitor of activator protein-1 (AP-1).

SR 19881 is a full agonist of ERRγ(EC50 value of 0.39 μM in a binding assay and an EC50 value of 4.7 μM in a cell-based assay).

SR 11023, an orally active PPAR γ antagonist, exhibits an IC 50 value of 109 nM and is significant in diabetes research [1].

Anti-c-Kit CD117 Antibody (SR-1) is a mouse IgG2a, κ chimeric antibody that specifically targets human c-Kit CD117. The recommended isotype control for this antibody is Mouse IgG2a kappa, Isotype Control.

SR 142948-C3-NHMe is the methylated form of SR 142948.

SR 146131 is a potent and selective agonist of the nonpeptide receptor.

SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).

SR 142948 dihydrochloride is a selective, orally active, non-peptide neurotensin receptor (NT) antagonist, featuring IC50 values of 1.19 nM, 0.32 nM, and 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. It effectively inhibits NT-induced inositol monophosphate formation in HT-29 cells (IC50 = 3.9 nM) and blocks NT-induced hypothermia, analgesia, and steering behavior in vivo. Furthermore, it demonstrates blood-brain barrier permeability, positioning it as a potential tool for psychiatric disorder research [1] [2].

NK3 receptor antagonist

SSR 146977 hydrochloride is a potent, selective antagonist of the tachykinin NK 3 receptor, and it can be utilized in research on psychiatric disorders and airway inflammation [1].

SR 140333 is a NK1 receptor antagonist.

SR 1555 is a novel RORγ-specific synthetic ligand.

SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.

SR 142948 is a neurotensin (NT) receptor antagonist.

SR13668 is a potent indole analog derived from indole-3-methanol (I3C), renowned for its natural anti-cancer properties but limited by poor metabolic characteristics. Designed to enhance the anti-cancer efficacy of I3C, SR13668 effectively inhibits Akt activation stimulated by growth factors. It exhibits strong oral anti-cancer activity across various cancer types, demonstrating both high safety and robust inhibitory effects.

SR 12460 is a lead NBD mimic, inhibiting the interaction between IKKβ and NEMO, suppressing TNF-α and LPS-induced NF-κB activation, and reducing LPS-induced acute pulmonary inflammation in mice.

α3β4 nAChR antagonist

Meclinertant (SR 48692) is a neurotensin receptor-1 (NT1) antagonist that blocks neurotensin-induced excitation and can be used to study neurological disorders.

Irbesartan (SR-47436) is an Angiotensin 2 Receptor Blocker whose mechanism of action involves antagonizing the Angiotensin 2 Receptor.

Rimonabant hydrochloride (SR 141716A) is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity.

Rupatadine (UR-12592) is a potent dual PAF H1 antagonist with Ki values of 0.55 μM in rabbit platelet membranes and 0.1 μM in guinea pig cerebellum membranes.

StemRegenin 1 (SR1) is an aryl hydrocarbon receptor (AhR) inhibitor.

Ex26 (S1P1-IN-Ex26) is a selective and potent sphingosine 1-phosphate receptor 1 (S1P1) antagonist that disrupts SR-B1-S1PR1 interactions and inhibits S1P-S1PR1 signaling. Ex26 is used in experimental autoimmune encephalomyelitis, atherosclerosis, and gastric cancer.